CRYBG1 and prostate carcinoma: AIM1 has been shown to be highly overexpressed in prostate cancer tissues, and cultured androgen-independent prostate cancer cells, indicating that AIM1 might be a potential therapeutic target for treatment of prostate cancer [51].